Calgary, Alberta October 28, 2024 – Northern RNA Inc. is excited to announce the signing of a Memorandum of Understanding (MOU) with Kaster Technologies Inc., a cutting-edge Canadian company specializing in digital tools for optimizing drug and life science manufacturing.
This MOU marks an exciting milestone for Northern RNA as we seek to strengthen our presence in Canada’s growing life sciences sector. Through this MOU, Northern RNA and Kaster Technologies will work together to drive meaningful impact by committing to joint activities that foster sector development and innovation. We will be actively sharing knowledge, expertise, and resources, all with the aim of enhancing research and development capabilities, expanding commercial opportunities, and driving diversification within the industry.
This strategic collaboration is designed to explore and develop mutual business opportunities that will not only benefit both organizations but also contribute to the growth and advancement of Canada’s life sciences, pharmaceutical, and manufacturing sectors. The partnership seeks to leverage Northern RNA’s expertise in scalable manufacturing of nucleic acid products, including mRNA and DNA, with Kaster Technologies advanced digital tools and industry insights aimed at improving operational efficiency and reducing global drug shortages.
Together, Northern RNA and Kaster Technologies aim to develop a robust collaboration that enhances Canada’s position as a leader in the global life sciences industry.
“We are excited to explore the tremendous opportunities ahead, driving forward innovation and advancements in Biomanufacturing” said Thomas Hansen MBA., Vice President Corporate Affairs Northern RNA, “In particular we are looking forward to working with Kaster Technologies to identify opportunities to apply their industry-leading digital tools at our Lipids Manufacturing Facility.”
“This partnership with Northern RNA will create new opportunities to strengthen sovereign manufacturing capabilities and advance the life sciences sector,” said Alexandre Clarizio, CEO at Kaster Technologies. “Pharma 5.0 is here, and this partnership will enable us to drive innovation together.”
This MOU marks the first step in a promising partnership, and both Parties look forward to the meaningful impact this collaboration will have on the life sciences sector.
Stay tuned for more updates as we embark on this exciting journey together!
#PartnershipForGrowth #LifeSciences #DrugDevelopment #Biomanufacturing #Innovation #Canada #Digitaltools #CDMO #ManufacturingaBetterFuture